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On page 233, left-hand column, second paragraph, line 17 
forward, it says:
“The most common reasons for discontinuation were 
dizziness, confusion, somnolence, and asthenia, with the 
highest proportion of withdrawals in patients receiving 
retigabine 1200 mg/kg.72 In RESTORE 1, where retigabine 
was used at 1200 mg/kg, urinary or renal disorders were 
observed in 12% of patients.”
In this passage, both instances of “retigabine 1200 mg/kg” 
should be “retigabine 1200 mg/day.”
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